

Institutional Analysis of Metaplastic Breast Cancer

Ashlyn M Alongi MD*, Jaron Pettis MD*, Amy Rivere MD*, Erin A Elder MD*, George Fuhrman MD*
Department of Surgery, Ochsner Clinic Foundation, New Orleans, LA

- 0.2-5% all invasive breast cancer
- Often treated like hormone negative breast cancer
- We hypothesize patients with metaplastic breast cancer are less likely to respond to neoadjuvant chemotherapy
- Retrospective review
- January 2012-July 1, 2022

Clinicopathologic characteristics of MBC and TNBC						
		TNBC (n=42)	%	MBC (n=22)	%	P-value
Age (years)	Median (range)	60 (35-87)		71 (38-92)		0.0315
Tumor size (cm)	Median	2 (0.4-4.6)		2.9 (0.8-15.6)		0.0071
Pathologic LN		18	43	4	18	0.0575
Chemotherapy	No	9	21	4	18	0.013
	Neoadjuvant	21	50	5	23	
	Adjuvant	12	29	13	59	
Response to Neoadjuvant Chemotherapy	No response	2	10	4	80	0.003
	Partial response	8	38	1	20	
	Complete response	11	52	0	0	

- Significantly less response among MBC who underwent NAC
- Rare disease, limited by small sample size
- Other treatment strategies: gene-expression profiling, targeted immunotherapy
- Future directions - meta-analysis and long-term clinical outcomes among these patients

